Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study
Among PWH on INSTI treatment, IVDUh, concurrent psychiatric illness, abacavir and RAL use increased the risk of CNS/NP AEs occurrence. PWH on BIC were less likely to experience CNS/NP AEs and related treatment discontinuations.
Authors
- Antonio Di Biagio (ORCID: https://orcid.org/0000-0003-1436-5089)
- Eleonora Sarchi
- Paolo Maggi (ORCID: https://orcid.org/0000-0002-8772-0136)
- Benedetto Maurizio Celesia (ORCID: https://orcid.org/0000-0002-6919-1955)
- Gabriele Forcina (ORCID: https://orcid.org/0009-0007-0385-2734)
- Giuseppe Vittorio De Socio (ORCID: https://orcid.org/0000-0001-8774-4843)
- Filippo Lagi (ORCID: https://orcid.org/0000-0003-0999-6070)
- Nicola Squillace (ORCID: https://orcid.org/0000-0002-7608-6045)
- Elena Ricci (ORCID: https://orcid.org/0000-0001-5279-0444)
- Laura Albini
- Barbara Menzaghi (ORCID: https://orcid.org/0000-0002-5073-6521)
- Elena Salomoni (ORCID: https://orcid.org/0000-0001-6094-2102)
- Giordano Madeddu (ORCID: https://orcid.org/0000-0001-6099-2273)
- Paolo Bonfanti (ORCID: https://orcid.org/0000-0001-7289-8823)
- Stefania Piconi (ORCID: https://orcid.org/0000-0001-7058-1048)
- Giovanni Francesco Pellicanò (ORCID: https://orcid.org/0000-0002-9640-8742)
- Giancarlo Orofino
Institutions
- University of Messina (IT)
- University of Sassari (IT)
- Fondazione Roma (IT)
- Ospedale Garibaldi (IT)
- Azienda Ospedaliera San Gerardo (IT)
- Alessandro Manzoni Hospital (IT)
- Ospedale Santa Maria Annunziata (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Gilead Sciences (Italy) (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1186/s12879-025-11090-3
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Gilead Sciences